Daptomycin for the treatment of surgical site infections

Surgery

Volumn 146, Issue 2, 2009, Pages 316-324

  Chamberlain, Ronald S ^a   Culshaw, Darren L ^b   Donovan, Brian J ^b   Lamp, Kenneth C ^b  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; DAPTOMYCIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ARTICLE; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOCCUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; SURGICAL WOUND INFECTION;

EID: 67650552677     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.03.037     Document Type: Article

References (29)

1. Klevens R.M., Edwards J.R., Richards Jr. C.L., Horan T.C., Gaynes R.P., Pollock D.A., et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122 (2007) 160-166
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 30 (2002) 458-475
3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 458-485
4. Bratzler D.W., Houck P.M., Richards C., Steele L., Dellinger E.P., Fry D.E., et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 140 (2005) 174-182
5. Kirkland K.B., Briggs J.P., Trivette S.L., Wilkinson W.E., and Sexton D.J. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 20 (1999) 725-730
6. Kaye K.S., Schmader K.E., and Sawyer R. Surgical site infection in the elderly population. Clin Infect Dis 39 (2004) 1835-1841
7. Petti C.A., Sanders L.L., Trivette S.L., Briggs J., and Sexton D.J. Postoperative bacteremia secondary to surgical site infection. Clin Infect Dis 34 (2002) 305-308
8. Lodise T.P., McKinnon P.S., Swiderski L., and Ryback M.J. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36 (2003) 1418-1423
9. Engemann J.J., Carmeli Y., Cosgrove S.E., Fowler V.G., Bronstein M.Z., Trivette S.L., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
10. Cantlon C.A., Stemper M.E., Schwan W.R., Hoffman M.A., and Qutaishat S.S. Significant pathogens isolated from surgical site infections at a community hospital in the Midwest. Am J Infect Control 34 (2006) 526-529
11. Patel M., Kumar R.A., Stamm A.M., Hoesley C.J., Moser S.A., and Waites K.B. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 45 (2007) 3431-3433
12. Popovich K.J., Weinstein R.A., and Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis 46 (2008) 787-794
13. Manian F.A., and Griesnauer S. Community-associated methicillin-resistant Staphylococcus aureus (MRSA) is replacing traditional health care-associated MRSA strains in surgical-site infections among inpatients. Clin Infect Dis 47 (2008) 434-435
14. Miller L.G., Perdreau-Remington F., Rieg G., Mehdi S., Perlroth J., Bayer A.S., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352 (2005) 1445-1453
15. Wang G., Hindler J.F., Ward K.W., and Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 (2006) 3883-3886
16. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60 (2007) 788-794
17. Cubicin [prescribing information] (2007), Cubist Pharmaceuticals, Lexington, Mass
18. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
19. Knapp AG, Kamepalli RK, Martone WJ, Yankelev S. A prospective, comparative study of daptomycin for the treatment of superficial and deep surgical site infections. Presented at: 26th Annual Meeting of the Surgical Infection Society, April 27-29, 2006, San Diego, CA.
20. sm) methodology. Am J Med 120 (2007) S4-S5
21. Forrest G.N., Donovan B.J., Lamp K.C., and Friedrich L.V. Clinical experience with daptomycin for the treatment of patients with documented Gram-positive septic arthritis. Ann Pharmacother 42 (2008) 213-217
22. Anderson D.J., Sexton D.J., Kanafani Z.A., Auten G., and Kaye K.S. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 28 (2007) 1047-1053
23. Gonzalez B.E., and Rueda A.M. Shelburne SA III, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 27 (2006) 1051-1056
24. Davis S.L., Perri M.B., Donabedian S.M., Manierski C., Singh A., Vager D., et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 45 (2007) 1705-1711
25. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., and Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144 (2006) 309-317
26. Weigelt J., Kaafarani H.M., Itani K.M., and Swanson R.N. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188 (2004) 760-766
27. Mwangi M.M., Wu S.W., Zhou Y., Sieradzki K., de Lencastre H., Richardson P., et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104 (2007) 9451-9456
28. Kim A., Suecof L.A., Sutherland C.A., Gao L., Kuti J.L., and Nicolau D.P. Penetration of daptomycin into soft tissues in diabetic versus healthy volunteers by in vivo microdialysis. Antimicrob Agents Chemother 52 (2008) 3941-3946
29. Wise R., Gee T., Andrews J.M., Dvorchik B., and Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 46 (2002) 31-33